Cargando…

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance

BACKGROUND: To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. METHODS: 20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washou...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xuan, Lu, Wen, Lu, Zijun, Shao, Xinyu, Hu, Chunhong, Shi, Bimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818885/
https://www.ncbi.nlm.nih.gov/pubmed/29541641
http://dx.doi.org/10.1155/2018/4019248
_version_ 1783301101045415936
author Du, Xuan
Lu, Wen
Lu, Zijun
Shao, Xinyu
Hu, Chunhong
Shi, Bimin
author_facet Du, Xuan
Lu, Wen
Lu, Zijun
Shao, Xinyu
Hu, Chunhong
Shi, Bimin
author_sort Du, Xuan
collection PubMed
description BACKGROUND: To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. METHODS: 20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washout treatment of metformin, 6-month exenatide treatment, and 6-month glargine treatment were administrated sequentially accompanied with previous metformin. Glucolipid metabolic parameters were compared among groups. Adipose distribution was quantified with computerized tomography according to anatomy, dividing into visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), adding up to total adipose tissue (TAT). RESULTS: The 6-month exenatide treatment dramatically ameliorated the glucose and lipid profile, improved insulin sensitivity, and mainly decreased VAT and also the ratio of VAT/SAT (RVS). The following 6-month glargine treatment increased VAT. The whole 12-month sequential treatment with exenatide and glargine added to metformin basically improved the insulin sensitivity and glucolipid control though VAT rebounded at the end, however without deteriorating the other parameters. CONCLUSION: Exenatide is an ideal treatment for obese type 2 diabetic patients in the aspect of adipose tissue distribution. Sequential treatment of exenatide and glargine could be an alternative for low-income patients who cannot afford GLP-1 agonist for long time. This trial is registered with ChiCTR-OOC-17013679.
format Online
Article
Text
id pubmed-5818885
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58188852018-03-14 Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance Du, Xuan Lu, Wen Lu, Zijun Shao, Xinyu Hu, Chunhong Shi, Bimin J Diabetes Res Clinical Study BACKGROUND: To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution. METHODS: 20 newly diagnosed obese type 2 diabetic patients were enrolled, and 2-month washout treatment of metformin, 6-month exenatide treatment, and 6-month glargine treatment were administrated sequentially accompanied with previous metformin. Glucolipid metabolic parameters were compared among groups. Adipose distribution was quantified with computerized tomography according to anatomy, dividing into visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), adding up to total adipose tissue (TAT). RESULTS: The 6-month exenatide treatment dramatically ameliorated the glucose and lipid profile, improved insulin sensitivity, and mainly decreased VAT and also the ratio of VAT/SAT (RVS). The following 6-month glargine treatment increased VAT. The whole 12-month sequential treatment with exenatide and glargine added to metformin basically improved the insulin sensitivity and glucolipid control though VAT rebounded at the end, however without deteriorating the other parameters. CONCLUSION: Exenatide is an ideal treatment for obese type 2 diabetic patients in the aspect of adipose tissue distribution. Sequential treatment of exenatide and glargine could be an alternative for low-income patients who cannot afford GLP-1 agonist for long time. This trial is registered with ChiCTR-OOC-17013679. Hindawi 2018-02-06 /pmc/articles/PMC5818885/ /pubmed/29541641 http://dx.doi.org/10.1155/2018/4019248 Text en Copyright © 2018 Xuan Du et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Du, Xuan
Lu, Wen
Lu, Zijun
Shao, Xinyu
Hu, Chunhong
Shi, Bimin
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
title Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
title_full Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
title_fullStr Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
title_full_unstemmed Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
title_short Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
title_sort exenatide with metformin ameliorated visceral adiposity and insulin resistance
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818885/
https://www.ncbi.nlm.nih.gov/pubmed/29541641
http://dx.doi.org/10.1155/2018/4019248
work_keys_str_mv AT duxuan exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance
AT luwen exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance
AT luzijun exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance
AT shaoxinyu exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance
AT huchunhong exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance
AT shibimin exenatidewithmetforminamelioratedvisceraladiposityandinsulinresistance